Pharma manager bets on post-vaccine hike in routine health appointments

While active health care investor Fondita banks on medical needs in the post-Covid-19 world, the first portfolio review after the pandemic's onset will be carried out in December at Seligson's passively managed pharmaceutical fund. "We are trying to interpret what will happen in the markets after there is a vaccination," Fondita's CEO says.

Photo: Pexels

Following a go-ahead from safety watchdogs to resume clinical trials for a Covid-19 vaccine candidate on Sunday, the share price of British-Swedish drugmaker AstraZeneca has experienced steady increase since Monday. The same day Pfizer announced it is likely the US will deploy a Covid-19 shot before the end of the year.

At Finnish asset manager Seligson, some 3.57 percent of the company's Global Top 25 Pharmaceutical funds and Fondita’s Healthcare fund 3.6 percent of portfolio is invested in AstraZeneca.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

New sustainability quant manager makes Stockholm key in global conquest: "ESG leadership coming from the Nordic region is really phenomenal"

US-based V-Square Quantitative Management using ESG data as fuel for its investment engine will run its global distribution from Stockholm. Here, the company's President and co-founder Mamadou-Abou Sarr helped a Swedish pension fund develop a low carbon equity strategy in 2013. Sarr tells AMWatch what the firm wants to achieve, and why he is comfortable with the big bill that comes along when buying tons of ESG data.

Further reading

Related articles

Trial banner

Latest news

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch